Savara Can be a scientific-stage biopharmaceutical company building therapies for unusual respiratory health conditions. Its lead product applicant is undoubtedly an immunostimulator called molgramostim. Molgramostim is in phase 3 clinical trials to treat autoimmune pulmonary alveolar proteinosis, or aPAP. The list of symbols provided around the site is updated https://financefeeds.com/duco-appoints-margaret-franco-as-chief-marketing-officer/